ERBB2 and cancer: The reduced viabilitynoted in both BT474 and BT-474-TR cell lines upon treatment with anti-HER2VHH-FcK relative to Trastuzumab suggests that the anti-HER2 VHH-FcKexhibits superior cytotoxicity against cancer cells.